Metamizol (dipyrone, optalgin) in pregnancy, is it safe? - A prospective comparative study

被引:27
作者
Bar-Oz, B
Clementi, M
Di Giantonio, E
Greenberg, R
Beer, M
Merlob, P
Arnon, J
Ornoy, A
Zimmerman, DM
Berkovitch, M [1 ]
机构
[1] Assaf Harofeh Med Ctr, Drug Consultat Ctr, Clin Pharmacol & Toxicol Unit, Zerifin, Israel
[2] Hadassa Univ Hosp, Dept Neonatol, Jerusalem, Israel
[3] Univ Padua, Genet Clin & Epidemiol, Serv Informaz Teratol, Padua, Italy
[4] Rabin Med Ctr, Petah Tiqwa, Israel
[5] Hadassah Med Sch, Minist Hlth, Rabin Med Ctr, Jerusalem, Israel
[6] Hebrew Univ Jerusalem, Hadassah Med Sch, Jerusalem, Israel
[7] Minist Hlth, Israeli Teratogen Informat Serv, Jerusalem, Israel
关键词
teratogenic effect; metamizol; pregnancy; congenital malformations;
D O I
10.1016/j.ejogrb.2004.07.004
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Aim: To assess the teratogenic effect of metamizol when used during the first trimester of pregnancy. Methods: One hundred and eight women who used metamizol during the first trimester of pregnancy were recruited from 4 teratogen information centers in Israel (3) and in Italy 0). The study group was paired for age. smoking habits and alcohol consumption with a comparative group exposed to acetaminophen. Results: Maternal demographics and history, birth weight, gestational age at delivery, rate of live births, spontaneous abortions and fetal distress were comparable in both groups. The rate of major malformations in the metamizol group (3%) did not differ significantly from the rate in the comparative group (2%) (P = 0.57, relative risk = 1.55. 95% confidence interval 0.20-9.05). Conclusions: Our data may suggest that exposure to metamizol during the first trimester of pregnancy is probably not associated with a significantly increased risk for malformations or spontaneous abortions. (c) 2004 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:176 / 179
页数:4
相关论文
共 26 条
[1]  
Alexander FE, 2001, CANCER RES, V61, P2542
[2]   Utilization pattern of metamizole in northern Sweden and risk estimates of agranulocytosis [J].
Bäckström, M ;
Hägg, S ;
Mjörndal, T ;
Dahlqvist, R .
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2002, 11 (03) :239-245
[3]  
CATALAN JL, 1995, MED CLIN-BARCELONA, V104, P541
[4]   Agranulocytosis and near fatal sepsis due to 'Mexican aspirin' (Dipyrone) [J].
Dorr, VJ ;
Cook, J .
SOUTHERN MEDICAL JOURNAL, 1996, 89 (06) :612-614
[5]   Dipyrone and agranulocytosis: what is the risk? [J].
Edwards, JE ;
McQuay, HJ .
LANCET, 2002, 360 (9344) :1438-1438
[6]  
EDWARDS JE, 2002, COCHRANE DATABASE SY, P3876
[7]   Morphological and biochemical action of dipyrone on rat placenta [J].
Espiridiao, S ;
Oliveira, RM ;
Doine, A ;
Simoes, MJ ;
Focchi, GRA ;
Neto, JE ;
Kopelman, BI ;
Kulay, L .
GENERAL PHARMACOLOGY, 1996, 27 (03) :505-507
[8]   Mutagenicity assay in Salmonella and in vivo sister chromatid exchange in bone marrow cells of mice for four pyrazolone derivatives [J].
Giri, AK ;
Mukhopadhyay, A .
MUTATION RESEARCH-GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS, 1998, 420 (1-3) :15-25
[9]   EFFECTS OF PH ON ANTIPYRINE TRANSFER ACROSS THE HUMAN PLACENTA EXVIVO [J].
GIROUX, M ;
CAMPISTRON, G ;
FAURE, F ;
DUMAS, JC ;
COULAIS, Y ;
DESPRATS, R ;
GRANDJEAN, H ;
HOUIN, G ;
PONTONNIER, G .
DEVELOPMENTAL PHARMACOLOGY AND THERAPEUTICS, 1990, 14 (03) :153-160
[10]   Agranulocytosis and other blood dyscrasias associated with dipyrone (metamizole) [J].
Hedenmalm, K ;
Spigset, O .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 58 (04) :265-274